Discover how Ozempic and other GLP-1 agonists may reduce the risk of obesity-associated cancers in a recent study of obese patients. Learn more about the potential cancer-preventive effects of these diabetes medications.

Discover Ro's new GLP-1 Supply Tracker, providing real-time insights into GLP-1 drug shortages. Learn how this tool helps manage medication availability as demand for weight loss drugs rises.

New research from the University of Aberdeen reveals how physical fitness influences the body's metabolism of saturated fat. Discover how exercise impacts fat utilization and improves overall metabolic health.

Discover strategies to mitigate the high costs of discontinuing GLP-1 medications. Learn how employers can plan for effective weight management and ensure long-term adherence.

Discover the latest breakthrough in obesity treatment as Novo Nordisk launches Wegovy® in Canada on May 6, 2024. Learn how this once-weekly injection can transform obesity management and support millions of Canadians. Explore the effectiveness, safety data, and patient eligibility for Wegovy®.

Discover the latest study findings revealing potential gastrointestinal risks associated with popular weight loss medications Ozempic and Wegovy. Learn about the study's implications for those considering these drugs for weight management

Unlock the secret to successful weight management with insights from a recent report published in Obesity that delves into the science of circadian rhythms and their impact on maximizing weight loss through strategic exercise timing. Discover the ideal workout hours recommended by experts for effective weight management and a healthier lifestyle.